Zentalis Pharmaceuticals, Inc.
ZNTL
$1.62
-$0.015-0.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 69.56% | -579.53% | -55.90% | 27.68% | 21.55% |
| Total Depreciation and Amortization | -51.07% | -19.14% | -5.93% | -7.76% | -4.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -99.15% | 129.10% | 199.45% | -74.01% | 3.71% |
| Change in Net Operating Assets | -162.49% | 111.29% | -168.91% | -251.87% | 358.08% |
| Cash from Operations | 1.23% | 37.21% | 2.21% | -13.91% | 55.67% |
| Capital Expenditure | -- | -- | 100.00% | 100.00% | 43.26% |
| Sale of Property, Plant, and Equipment | 767.69% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13.85% | -34.29% | 177.07% | 141.11% | -52.76% |
| Cash from Investing | -11.92% | -34.24% | 176.75% | 141.08% | -52.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -23.79% | -- | -70.23% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | 2,600.00% | -- | -70.23% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -576.56% | -16.18% | 91.02% | 102.75% | -100.28% |